Active Biotech Interim Report Q1 2024
FIRST QUARTER IN BRIEF
- Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis
- The expansion cohort of the study in multiple myeloma is ongoing according to plan
EVENTS AFTER THE END OF THE PERIOD
- Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)
FINANCIAL SUMMARY
SEK M | Jan-Mar | Full year | |
2024 | 2023 | 2023 | |
Net sales | – | – | – |
Operating profit/loss | -10.7 | -11.8 | -46.5 |
Profit/loss after tax | -10.5 | -11.5 | -45.8 |
Earnings per share (SEK) | -0.03 | -0.04 | -0.17 |
Cash and cash equivalents (at close of period) | 25.4 | 30.2 | 36.2 |
The report is also available at www.activebiotech.com.
This information was provided to the media, through the agency of the contact persons set out below, for publication on May 8, 2024 at 18.00 CET.